The Economic Times Healthcare and Biotech News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Zydus Lifesciences launches generic drug for overactive bladder in US market
Zydus is among the first suppliers to launch the generic version of Mirabegron extended-release tablets (USP 25 mg) in the US market. The company is also preparing to launch the 50 mg tablets in the market. Mirabegron is indicated for the treatment of Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 22, 2024 Category: Pharmaceuticals Source Type: news

USFDA pulls up Natco Pharma for manufacturing lapses at Telangana plant
Natco Pharma's Telangana plant violated cleanliness and sterilisation standards at Kothur Village facility per USFDA. The warning letter mentioned cross-contamination, inadequate cleaning procedures, and the need for comprehensive investigations and corrective actions. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 21, 2024 Category: Pharmaceuticals Source Type: news

Healthcare needs tailored financing, knowledge and partnerships: World Bank President Ajay Banga
Healthcare needs tailored financing, knowledge and partnerships, says World Bank President Ajay Banga. He said, during and after COVID, financing for healthcare has increased but to make healthcare affordable and bring it to the reach of all, it needs knowledge and partnerships along with financing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 19, 2024 Category: Pharmaceuticals Source Type: news

Middle East crisis escalation may hurt pharma exports
While exports have not been affected so far, the next few days are crucial because, if there is serious escalation in the conflict, it could impact the whole Middle East and North Africa (MENA) region. Many Indian pharma companies have a significant presence in the region. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 18, 2024 Category: Pharmaceuticals Source Type: news

CDCSO issues distribution guidelines for pharma products in market to curb substandard medicines
The Central Drugs Standard Control Organisation (CDSCO) has released draft guidelines on good distribution practices to prevent the introduction of spurious, adulterated, and sub-standard pharmaceutical products in the market. The guidelines are in line with the WHO Technical Report Series on good storage and distribution practices for such products. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 18, 2024 Category: Pharmaceuticals Source Type: news

Govt mulls allowing sale of common medicines in general stores
India's committee, under Atul Goel's leadership, is pioneering the development of guidelines for over-the-counter medicines to improve accessibility. This initiative marks a significant step towards streamlining non-prescription drug regulations. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 18, 2024 Category: Pharmaceuticals Source Type: news

Complaint filed against Natco Pharma in US by Fresenius Kabi
Natco Pharma faces a legal complaint from Fresenius Kabi in the US District Court regarding the marketing of Diazepam injection prefilled syringe. Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH filed the complaint against Natco Pharma USA LLC (formerly Dash Pharmaceuticals LLC). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 18, 2024 Category: Pharmaceuticals Source Type: news

Biocon partners Biomm to commercialise diabetes drug in Brazil
Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop, manufacture, and supply the drug, while Biomm will obtain regulatory approval and commercialization in Brazil. Biomm focuses on developing, manufacturing, and commercialising complex biotech and biosimilar drug products. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 17, 2024 Category: Pharmaceuticals Source Type: news

Delhi HC upholds injunction against Glenmark Pharma
Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use drug names “Istamet” and “Indamet”, respectively, which Sun Pharma finds to be deceptively similar and confusing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 17, 2024 Category: Pharmaceuticals Source Type: news

HC upholds its earlier order on asthma drug Indamet against Glenmark Pharma
Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use drug names “Istamet” and “Indamet”, respectively, which Sun Pharma finds to be deceptively similar and confusing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 17, 2024 Category: Pharmaceuticals Source Type: news

Jubilant gets VAI classification from USFDA for Roorkee unit
As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 17, 2024 Category: Pharmaceuticals Source Type: news

Delius Pharma registers 35% growth in sales, plans IPO in next 3 years
Delius Pharma registered a 35 percent rise in sales in FY23 to 24, with plans to set up multiple manufacturing units in India for finished formulation and API production. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 16, 2024 Category: Pharmaceuticals Source Type: news

ChrysCap buys small stake in generics company La Renon for Rs 600 cr
Incorporated in 2007 by Pankaj Singh, La Renon is engaged in the manufacturing and marketing of branded generic formulations. ChrysCapital is close to acquiring a minority stake in La Renon Healthcare via secondary sale of shares, at a valuation of Rs 6,500 crore ($800 million), ET first reported on February 12. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 15, 2024 Category: Pharmaceuticals Source Type: news

India's pharma exports to US surge 15% in 11 months of FY24
The pace of exports has more than doubled from the 6.18% growth in the same period of FY23, according to estimates by Pharmaceutical Export Promotion Council (Pharmexcil). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 14, 2024 Category: Pharmaceuticals Source Type: news

Glenmark recalls 6,528 bottles of blood pressure drug in US
As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 14, 2024 Category: Pharmaceuticals Source Type: news